Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp (ATNF) is a clinical-stage biotechnology company pioneering treatments for inflammatory diseases, fibrosis, and pain through advanced therapeutic platforms. This page serves as the definitive source for official news and developments across the company’s scientific research and blockchain-enabled iGaming initiatives.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, financial announcements, and strategic partnerships. Key focus areas include the company’s anti-TNF fibrosis research, synthetic cannabidiol analogs development, and expansion into blockchain-based gaming technology solutions.
All content is curated to provide accurate, compliance-focused information without speculative commentary. Regular updates ensure stakeholders maintain current awareness of ATNF’s progress in both biotechnology and digital innovation sectors.
Bookmark this page for direct access to press releases, earnings reports, and operational updates from 180 Life Sciences Corp. Check back frequently for the latest developments shaping this innovative dual-sector enterprise.
180 Life Sciences Corp. (NASDAQ: ATNF) has received an extension from the Nasdaq Listing Qualifications Panel to regain compliance with continued listing requirements. The company now has until September 20, 2024 to meet the minimum stockholders' equity requirement of $2.5 million. This extension allows 180 Life Sciences to continue trading on Nasdaq while working to meet the Equity Rule.
The company had previously received a delist determination letter on May 14, 2024, but appealed the decision. While the Hearings Panel has granted this extension, there is no guarantee that 180 Life Sciences will meet the deadlines or conditions imposed. The Nasdaq Listing and Hearing Review Council may also review the decision within 45 calendar days.
180 Life Sciences announced that Nasdaq's Hearings Panel has granted the company an extension to regain compliance with Nasdaq's continued listing requirements, particularly the minimum stockholders’ equity rule of $2.5 million, by July 31, 2024. The company was initially notified of non-compliance on November 15, 2023, and was unable to meet the equity requirement by the extended deadline of May 13, 2024. Consequently, a delist determination was issued on May 14, 2024. Following an appeal, the delisting action was stayed pending the Hearings Panel's decision, which has now granted the company additional time to comply. However, there is no guarantee that the company will meet these requirements.
